| Literature DB >> 35904697 |
Yanhong Hu1,2, Hongtao Lei2, Sai Zhang1, Jiabao Ma1, Soyeon Kang1, Liangqin Wan1, Fanghe Li1, Fan Zhang1, Tianshi Sun1, Chujun Zhang1, Weihong Li3.
Abstract
Recently, necroptosis has emerged as one of the important mechanisms of ischemia stroke. Necroptosis can be rapidly activated in endothelial cells to cause vascular damage and neuroinflammation. Panax notoginseng saponins (PNS), an ingredient extracted from the root of Panax notoginseng (Burk.) F.H. Chen, was commonly used for ischemic stroke, while its molecular mechanism and targets have not been fully clarified. Our study aimed to clarify the anti-necroptosis effect of PNS by regulating RIP1-RIP3-MLKL signaling pathway in brain microvascular endothelial cells (BMECs) subjected to transient oxygen-glucose deprivation (OGD/resupply [R]). In vitro, the necroptosis model of rat BMECs was established by testing the effect of OGD/R in the presence of the pan-caspase inhibitor z-VAD-FMK. After administration of PNS and Nec-1, cell viability, cell death modality, the expression of RIP1-RIP3-MLKL pathway and mitochondrial membrane potential (Δψm) level were investigated in BMECs upon OGD/R injury. The results showed that PNS significantly enhanced cell viability of BMECs determined by CCK-8 analysis, and protected BMECs from necroptosis by Flow cytometry and TEM. In addition, PNS inhibited the phosphorylation of RIP1, RIP3, MLKL and the downstream expression of PGAM5 and Drp1, while similar results were observed in Nec-1 intervention. We further investigated whether PNS prevented the Δψm depolarization. Our current findings showed that PNS effectively reduced the occurrence of necroptosis in BMECs exposed to OGD/R by inhibition of the RIP1-RIP3-MLK signaling pathway and mitigation of mitochondrial damage. This study provided a novel insight of PNS application in clinics.Entities:
Keywords: Brain microvascular endothelial cells (BMECs); Necroptosis; Oxygen-glucose deprivation/resupply (OGD/R); Panax notoginseng saponin (PNS); RIP1-RIP3-MLKL signaling pathway
Mesh:
Substances:
Year: 2022 PMID: 35904697 DOI: 10.1007/s11064-022-03675-0
Source DB: PubMed Journal: Neurochem Res ISSN: 0364-3190 Impact factor: 4.414